Genomic Health, Epic Sciences: positive coverage determination for test

Epic Sciences and Genomic Health announced that Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies, has issued a positive final local coverage determination, or LCD, for the Oncotype DX AR-V7 Nucleus Detect test. The final LCD recommends Medicare coverage for use of the test effective December 10, 2018, throughout the United States to help determine which patients with metastatic castrate resistant prostate cancer, or mCRPC, may benefit from continued androgen receptor signaling inhibitor, or ARSi, therapy, such as enzalutamide, abiraterone and apalutamide, as well as those who are resistant who may benefit from chemotherapy.
https://thefly.com/landingPageNews.php?id=2812389